Time course of urinary neopterin in a non-Hodgkin's lymphoma patient during chemotherapy and radiotherapy
Language English Country Great Britain, England Media print
Document type Case Reports, Journal Article
PubMed
15149166
Knihovny.cz E-resources
- MeSH
- Time Factors MeSH
- Cyclophosphamide administration & dosage MeSH
- Doxorubicin administration & dosage MeSH
- Combined Modality Therapy MeSH
- Creatinine urine MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma, Non-Hodgkin drug therapy radiotherapy urine MeSH
- Neopterin urine MeSH
- Prednisolone administration & dosage MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage therapeutic use MeSH
- Vincristine administration & dosage MeSH
- Chromatography, High Pressure Liquid MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Creatinine MeSH
- Neopterin MeSH
- Prednisolone MeSH
- Vincristine MeSH
The objective of this study was to follow urinary neopterin in a patient affected by non-Hodgkin's lymphoma during the three months treatment from the onset of the disease. In the study a patient affected by non-Hodgkin's lymphoma in Stage IV (centrocyto-centroblastic type) was enrolled. He was treated with combined chemotherapy and local radiotherapy. Neopterin was measured by high performance liquid chromatography in the first morning urine specimens. The time course of urinary neopterin levels ranged from 110 to 524 micromol x mol(-1) creatinine (mean 261, SD 67.5 micromol x mol(-1) creatinine). Over 70 % of the received values were higher than the upper limit of normal excretion of healthy subjects. Longitudinal analysis showed a relatively big variance of urinary neopterin with a tendency of decrease during the treatment. The significant decrease of urinary neopterin was observed till after the radiotherapy period which followed the chemotherapy period. In conclusions, the response to the therapy was accompanied by a reversal tendency of neopterin excretion to physiological values. This study confirms neopterin as a suitable additional parameter for the control of non-Hodgkin's lymphoma therapy.